Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
VGFT-OD-1009
Phase 3 small_molecule completed
Quick answer
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) for Diabetic Macular Edema is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Diabetic Macular Edema
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed